CRISPR Therapeutics Appoints CFO
This article was originally published in Scrip
CRISPR Therapeutics has appointed Marc Becker chief financial officer (CFO); he joins the company from rEVO Biologics, where he was CFO and senior vice president. Prior to this, he spent 10 years at Genzyme, most recently serving as finance director for the UK and Ireland before becoming the vice president of finance for Genzyme's renal and endocrine business in the US.
Register for our free email digests: